Cargando…

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination

Background: Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in advanced melanoma patients who showed progressive disease upon experimental dendritic cell (DC) vaccination. Methods: Retrospective analysis of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boudewijns, Steve, Koornstra, Rutger H. T., Westdorp, Harm, Schreibelt, Gerty, van den Eertwegh, Alfons J. M., Geukes Foppen, Marnix H., Haanen, John B., de Vries, I. Jolanda M., Figdor, Carl G., Bol, Kalijn F., Gerritsen, Winald R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007966/ https://www.ncbi.nlm.nih.gov/pubmed/27622070 http://dx.doi.org/10.1080/2162402X.2016.1201625

Ejemplares similares

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy
por: Schreibelt, Gerty, et al.
Publicado: (2013)

Immunological responses to adjuvant vaccination with combined CD1c(+) myeloid and plasmacytoid dendritic cells in stage III melanoma patients
por: Bloemendal, Martine, et al.
Publicado: (2021)

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
por: van Willigen, Wouter W., et al.
Publicado: (2018)

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination
por: van Willigen, Wouter W., et al.
Publicado: (2020)

Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients
por: Bol, Kalijn, et al.
Publicado: (2015)

Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition
por: Tel, Jurjen, et al.
Publicado: (2016)

Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma
por: Boudewijns, Steve, et al.
Publicado: (2014)

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
por: Boudewijns, Steve, et al.
Publicado: (2020)

High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
por: Westdorp, Harm, et al.
Publicado: (2020)

Opportunities for immunotherapy in microsatellite instable colorectal cancer
por: Westdorp, Harm, et al.
Publicado: (2016)

PTEN Hamartoma Tumor Syndrome and Immune Dysregulation()()()
por: Eissing, Marc, et al.
Publicado: (2018)

Naturally circulating dendritic cells to vaccinate cancer patients
por: Bol, Kalijn F., et al.
Publicado: (2013)

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
por: van Wilpe, Sandra, et al.
Publicado: (2021)

Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets
por: Wimmers, Florian, et al.
Publicado: (2014)

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

Lactate dehydrogenase: a marker of diminished antitumor immunity
por: Van Wilpe, Sandra, et al.
Publicado: (2020)

Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome
por: Gorris, Mark A J, et al.
Publicado: (2022)

Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib
por: Sweep, Mark W. D., et al.
Publicado: (2023)

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
por: Westdorp, Harm, et al.
Publicado: (2019)

Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens
por: Westdorp, Harm, et al.
Publicado: (2014)

Primary Human Blood Dendritic Cells for Cancer Immunotherapy—Tailoring the Immune Response by Dendritic Cell Maturation
por: Sittig, Simone P., et al.
Publicado: (2015)

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
por: Santegoets, Saskia JAM, et al.
Publicado: (2014)

Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy
por: Wimmers, Florian, et al.
Publicado: (2014)

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product
por: Lindenberg, Melanie A., et al.
Publicado: (2018)

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy
por: Bloemendal, Martine, et al.
Publicado: (2019)

A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets
por: Sittig, Simone P., et al.
Publicado: (2016)

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
por: Bol, Kalijn F., et al.
Publicado: (2019)

Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination
por: Aarntzen, Erik HJG, et al.
Publicado: (2013)

S48. Biomarker development for ipilimumab and prostate GVAX treatment
por: de Gruijl, T, et al.
Publicado: (2014)

T cell landscape within primary melanoma as a biomarker of survival after cancer vaccination in patients with metastatic disease
por: Vasaturo, Angela, et al.
Publicado: (2015)

A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
por: Creemers, Jeroen H A, et al.
Publicado: (2021)

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation
por: Retèl, Valesca P., et al.
Publicado: (2018)

Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer
por: van Wilpe, Sandra, et al.
Publicado: (2021)

Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG
por: Wefers, Christina, et al.
Publicado: (2018)

Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer
por: Bödder, Johanna, et al.
Publicado: (2021)

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
por: Geukes Foppen, Marnix H, et al.
Publicado: (2018)

Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients
por: Wimmers, Florian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hn3le79tdgq51jd96omkhnv4vp